SCHEMBL3173952

SCHEMBL3173952

CC(=O)Nc1ccc(C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)O)C(C)C)c(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.47
CYP2D6 P10635 2/20 0.47
CYP2C9 P11712 2/20 0.47
CYP2C19 P33261 2/20 0.47
CYP1A2 P05177 1/20 0.47
NPC1 O15118 1/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
TAAR1 Q96RJ0 1/20 0.45
ELANE P08246 1/20 0.44
HTT P42858 1/20 0.41
CMA1 P23946 2/20 0.41
PREP P48147 3/20 0.41
KCNH2 Q12809 1/20 0.40
FAP Q12884 1/20 0.40
ALDH1A1 P00352 1/20 0.40
THRB P10828 1/20 0.40
DPP4 P27487 1/20 0.40
DPP8 Q6V1X1 1/20 0.40
DPP9 Q86TI2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3181879 0.89 PREP (0.52) CYP3A4CYP2D6CYP2C9CYP2C19NPC1
SCHEMBL3181510 0.88 CYP3A4 (0.46) CYP3A4CYP2D6CYP2C9CYP2C19CYP1A2
SCHEMBL8288981 0.86 NPC1 (0.45) CYP3A4CYP2D6CYP2C9CYP2C19CYP1A2
SCHEMBL8288844 0.85 CASP1 (0.44) CYP3A4CYP2D6CYP2C9CYP2C19CYP1A2
SCHEMBL3171830 0.85 MEN1 (0.55) MEN1KMT2ATAAR1
SCHEMBL3166523 0.84 ATM (0.47) CYP3A4CYP2D6CYP2C9CYP2C19CYP1A2
SCHEMBL3182474 0.84 NPC1 (0.46) CYP3A4CYP2D6CYP2C9CYP2C19CYP1A2
SCHEMBL20484559 0.83 CMA1 (0.55) MEN1KMT2ATAAR1CMA1PREP
SCHEMBL18620667 0.83 CMA1 (0.55) MEN1KMT2ATAAR1CMA1PREP
SCHEMBL3172466 0.81 CYP2C19 (0.45) CYP3A4CYP2D6CYP2C9CYP2C19CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100105914-A1 CASPASE INHIBITORS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-04-29 US disclosed
US-7652153-B2 Use in controlling apoptosis, as antiinflammatory agents, in treating autoimmune disease, as antiischemic agents, in treating cardiovascular disorders; for example, (S,S)-3-[2-(3-Acetylamino-2-oxo-2H-pyridin-1-yl)-butyrylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid VERTEX PHARMACEUTICALS INCORPORATED 2010-01-26 US disclosed
US-20050233979-A1 Caspase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105914-A1 CASPASE INHIBITORS AND USES THEREOF CASP1, CASP5, CASP3 CYP3A4 171/4885CYP2D6 756/4885CYP2C9 274/4885
US-20050233979-A1 Caspase inhibitors and uses thereof CASP1, CASP5, CASP3 CYP3A4 155/4885CYP2D6 643/4885CYP2C9 227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.